Related Experiment Video
Updated: Jun 3, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial
Flávio D Fuchs1, Sandra C Fuchs, Leila B Moreira
1Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. ffuchs@hcpa.ufrgs.br
Insights
This study investigated if low-dose diuretics can prevent hypertension and cardiovascular events in pre-hypertensive individuals. Early use of blood pressure-lowering drugs may be a key public health strategy.
Area of Science:
- Cardiology
- Public Health
- Pharmacology
Background:
- Pre-hypertension increases cardiovascular risk and often progresses to hypertension.
- Non-drug interventions for hypertension prevention have shown limited effectiveness.
- Blood pressure-lowering agents can reduce cardiovascular events in high-risk patients and prevent hypertension.
Purpose of the Study:
- To evaluate the efficacy, safety, and feasibility of a population-based intervention to prevent hypertension incidence.
- To assess the prevention of target-organ damage in individuals with pre-hypertension.
- To investigate the role of early pharmacological intervention in cardiovascular health.
Main Methods:
- A randomized, double-blind, placebo-controlled trial (PREVER-prevention) involving 1250 participants aged 30-70 with pre-hypertension.
- Intervention arms: chlorthalidone 12.5 mg plus amiloride 2.5 mg versus identical placebo.
- Primary outcomes: hypertension incidence, adverse events, microalbuminuria, and left ventricular hypertrophy. Secondary outcomes: fatal/non-fatal cardiovascular events.
Main Results:
- The study is ongoing; results are pending.
- The trial is designed to detect a 40% reduction in hypertension incidence.
- Sample size: 625 participants per group, powered for 85% with P alpha of 5%.
Conclusions:
- Early use of diuretics may prevent hypertension and cardiovascular events in pre-hypertensive individuals.
- This intervention, if proven effective and safe, could form the basis of a public health program in Brazil.
- Pharmacological prevention of hypertension is a potential strategy for reducing cardiovascular disease burden.
Background:
Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a population-based intervention to prevent the incidence of hypertension and the development of target-organ damage.
Methods:
This is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years, with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo. The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625 participants per group. The project was approved by the Ethics committee of each participating institution.
Discussion:
The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a population-based perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil.
Trial Registration:
Clinical Trials NCT00970931.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension V: Nursing Management
Pre-Procedural Guidelines for Assessing Blood Pressure
Hypertension III: Clinical Manifestations and Diagnostic Studies
Coronary Artery Disease IV: Preventive Measures
Hypertension I: Introduction